Antifungal Susceptibility Testing and Identification

Kidd, Sarah; Crawford, Lucy C.; Halliday, Catriona

doi:10.1016/j.idc.2021.03.004

Cited by 16 publications

(17 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the absence of a clinical breakpoint, AST-adjusted antifungal therapy is recommended with low-quality evidence [ 66 ]. Although in some cases AST has been obtained and used to guide antifungal therapy [ 36 , 39 , 40 , 56 ], no recommendation regarding AST in Trichoderma spp.…”

Section: Discussionmentioning

confidence: 99%

Trichoderma spp.-Related Pneumonia: A Case Report in Heart–Lung Transplantation Recipient and a Systematic Literature Review

Burzio

Balzani

Montrucchio

et al. 2023

JoF

View full text Add to dashboard Cite

Opportunistic and hospital-acquired infections are common among recipients of solid organ transplantation. New pathogens are increasingly reported in the intensive care unit (ICU) population. We report a case of a patient who developed Trichoderma spp.-related pneumonia (TRP) after heart–lung transplantation. In the absence of antifungal susceptibility testing, TRP was confirmed by histological examination, and empirical therapy with voriconazole and caspofungin was swiftly initiated. Complete resolution of pneumonia was obtained after prolonged combination therapy. Given the lack of guidelines, we conducted a systematic review to elucidate the diagnostic and therapeutic strategies to apply during Trichoderma infection. After deduplication and selection of full texts, we found 42 articles eligible for the systematic review. Pneumonia seems to be the most common clinical manifestation (31.8%). The most used antifungal therapy was amphotericin B, while combination therapy was also reported (27.3%). All the patients were immunocompromised except for one case. Despite the rarity of Trichoderma spp. infection, the increase in invasive fungal infections is of growing importance in ICU, considering their impact on mortality and the emergence of antifungal resistance. In the absence of prospective and multicenter studies, a review can provide useful insight regarding the epidemiology, clinical manifestations, and management of these unexpected challenges.

show abstract

Section: Discussionmentioning

confidence: 99%

Trichoderma spp.-Related Pneumonia: A Case Report in Heart–Lung Transplantation Recipient and a Systematic Literature Review

Burzio

Balzani

Montrucchio

et al. 2023

JoF

View full text Add to dashboard Cite

show abstract

“…Considering that azole use by agricultural and commercial sectors has contributed to azole resistance it is essential to prevent the application of structurally related fungicides [ 153 ]. The emergence of medically induced in-host-acquired azole resistance could be restricted through recently improved diagnostics, along with the detection of mutations indicating resistance [ 245 , 246 ].…”

Section: Discussionmentioning

confidence: 99%

Novel Treatment Approach for Aspergilloses by Targeting Germination

Verburg

Neer

Duca

et al. 2022

JoF

View full text Add to dashboard Cite

Germination of conidia is an essential process within the Aspergillus life cycle and plays a major role during the infection of hosts. Conidia are able to avoid detection by the majority of leukocytes when dormant. Germination can cause severe health problems, specifically in immunocompromised people. Aspergillosis is most often caused by Aspergillus fumigatus (A. fumigatus) and affects neutropenic patients, as well as people with cystic fibrosis (CF). These patients are often unable to effectively detect and clear the conidia or hyphae and can develop chronic non-invasive and/or invasive infections or allergic inflammatory responses. Current treatments with (tri)azoles can be very effective to combat a variety of fungal infections. However, resistance against current azoles has emerged and has been increasing since 1998. As a consequence, patients infected with resistant A. fumigatus have a reported mortality rate of 88% to 100%. Especially with the growing number of patients that harbor azole-resistant Aspergilli, novel antifungals could provide an alternative. Aspergilloses differ in defining characteristics, but germination of conidia is one of the few common denominators. By specifically targeting conidial germination with novel antifungals, early intervention might be possible. In this review, we propose several morphotypes to disrupt conidial germination, as well as potential targets. Hopefully, new antifungals against such targets could contribute to disturbing the ability of Aspergilli to germinate and grow, resulting in a decreased fungal burden on patients.

show abstract

“…6. RESISTENCIA ANTIMICROBIANA Pinos, K., Zhagñay D., Calderón J., Parra, M. ISBN: 978-987-82912-6-0 90 donde se evidencia que la resistencia hacia algunos fármacos va en constante crecimiento, como el voriconazol, el fluconazol, la Anfotericina B, entre otras (16,17).…”

Section: Principales Microorganismos Farmacorresistentes Fúngicosunclassified

Resistencia Antimicrobiana

Larrea¹,

Segarra²,

Sisalima³

et al. 2023

Infectología Clínica

View full text Add to dashboard Cite

Resumen: La resistencia antimicrobiana constituye un problema de salud pública, es un proceso en el cual un microorganismo sobrevive ante los efectos de antimicrobianos, un mecanismo de supervivencia, disminuyendo la capacidad microbicida del antimicrobiano, siendo una temática importante para analizarse hoy en día, por lo cual es necesario realizar esta revisión. Existen diferentes mecanismos de resistencia como a nivel del material genético tenemos limitar su acceso, deshacerse del fármaco, destruir el medicamento, eludir efectos del medicamento y cambiar los objetivos del medicamento; en cambio a nivel extracelular fabricar biopelículas, intervención del sistema quorum sensing; a nivel de la envoltura celular, impermeabilidad de membranas, porinas de membranas, bombas de expulsión e inhibición de la síntesis de la pared celular; y a nivel intracelular tenemos sistemas de protección ribosomal y modificación del sitio activo. La bacteria farmacorresistente más destacada es la Escherichia Coli, siendo las ß-lactamasas de espectro extendido el tipo de resistencia más común a nivel de América y el mundo. En relación a virus, producen inmunosupresión, por tal motivo se relaciona especialmente con el Virus de la Inmunodeficiencia Humana. En relación con los hongos, se ha reconocido a la Cándida Albincans como el microorganismo más frecuente farmacorresistente. Y con relación a los parásitos, tenemos a Plasmodium falciparum y Schistosoma spp. Al tener una gran magnitud y ser una problemática creciente, se debe tomar en cuenca planes, guías, campañas, vigilancia epidemiológica, educación profesional médica y a la sociedad, sobre las complicaciones que podríamos evitar si estamos correctamente informados.

show abstract

Antifungal Susceptibility Testing and Identification

Cited by 16 publications

References 97 publications

Trichoderma spp.-Related Pneumonia: A Case Report in Heart–Lung Transplantation Recipient and a Systematic Literature Review

Trichoderma spp.-Related Pneumonia: A Case Report in Heart–Lung Transplantation Recipient and a Systematic Literature Review

Novel Treatment Approach for Aspergilloses by Targeting Germination

Resistencia Antimicrobiana

Contact Info

Product

Resources

About